Strong Revenue Performance
Bruker's Q1 2025 reported revenues increased 11% year-over-year to $801.4 million, with CER revenue growth of 12.5% year-over-year.
Bruker Scientific Instruments Segment Growth
The BSI segment reported 5.1% organic revenue growth, driven by strong performances in the BioSpin and CALID groups.
Innovative Product Launches
New products were launched in spatial biology, cellular analysis, NMR, microbiology, and molecular diagnostics, enhancing Bruker's high-value offerings.
Order Book and Backlog
Bruker reported a strong order book with a backlog of approximately seven months, providing a buffer for future quarters.